Appointments • Support Our Research

Arthritis Information

Support Research at the Johns Hopkins Arthritis Center

  • Disease Information
    • Rheumatoid Arthritis
    • Psoriatic Arthritis
    • Ankylosing Spondylitis
    • Osteoarthritis
    • Gout
    • Lyme Disease
    • Osteoporosis
  • Patient Corner
    • Arthritis Drug Information Sheets
    • Managing Your Arthritis
    • Educational Videos for Patients
  • Ask The Expert
  • Physician Corner
    • Rheumatology Conference
  • Our Research
    • Patient-Centered Outcomes Research
    • Research Studies
    •  The Camille Julia Morgan Arthritis Research and Education Fund
  • About Us
    • Appointment Information
    • Contact Us
    • Our Faculty
    • Our Staff
    • Rheumatology Specialty Centers
You are here: Home / Archives for Arthritis News / Rheumatoid Arthritis News

Leflunomide and Pregnancy Outcomes Explored

May 24, 2010 By Jon Giles, MD

Leflunomide use during early pregnancy is associated with fetal malformations in animal studies and is classified as a pregnancy category X by the U.S. Food and Drug Administration.  However, little is known about pregnancy outcomes in humans exposed to leflunomide in early pregnancy, particularly in those who receive “wash-out” with cholestyramine (a drug sequestrant).   Here, […]

Targeting Interleukin-17 Studied in Rheumatoid Arthritis

April 29, 2010 By Jon Giles, MD

Recently, it has been recognized that a subset of T cells producing the cytokine IL-17 contribute to the pathogenesis of rheumatoid arthritis (RA).  Animal studies have suggested that blockade of IL-17 may reduce the inflammatory signs and symptoms of inflammatory arthritis and reduce bone erosion.  Here, Genovese et al report Phase I/II data for LY2439821, […]

Does Tuberculosis Risk Differ Among TNF Inhibitors?

March 28, 2010 By Jon Giles, MD

Reactivation of latent tuberculosis is a recognized risk of TNF inhibitor use.  While there has been circumstantial evidence of greater risk with the monoclonal antibody TNF inhibitors (e.g. infliximab and adalimumab) compared with decoy receptor TNF inhibitors (e.g. etanercept), there have been few direct comparisons.  Here, Dixon et al (Ann Rheum Dis 2010; 69: 522-528) […]

Immunization Responses with Rituximab Explored

February 28, 2010 By Jon Giles, MD

Treatment with rituximab, a monoclonal antibody targeting CD20+ B cells, could adversely affect immunization responses by dampening the antibody response from new vaccination or reducing pre-formed antibody from prior vaccination.  However, little systematic investigation of immunization responses has been undertaken.  Here, two studies concurrently published in Arthritis & Rheumatism explore responses after influenza vaccination (van […]

FDA Approves Tocilizumab for Treatment of Rheumatoid Arthritis

January 11, 2010 By Jon Giles, MD

On January 8, 2010, the U.S. Food and Drug Administration approved tocilizumab (to be marketed under the trade name of Actemra) for the treatment of patients with moderate to severe rheumatoid arthritis who have had inadequate clinical responses to treatment with TNF inhibitors.  Tocilizumab is a humanized monoclonal antibody directed against the receptor for IL-6, […]

High Disease Activity During Pregnancy Associated with Lower Birth Weight

December 15, 2009 By Jon Giles, MD

Rheumatoid arthritis disease activity tends to improve during pregnancy, even when disease modifying agents are stopped.  However, a minority of women with rheumatoid arthritis will continue to have active disease during pregnancy, and may require additional immunosuppression.  Prior studies have yielded conflicting reports on the influence of active disease during pregnancy.  Here, de Man et […]

Surveillance Study Reports No Increase in Cancer Risk Over First Six years of TNF Inhibitor Use

November 30, 2009 By Jon Giles, MD

While most observational studies have not demonstrated an increase in malignancy independently associated with TNF inhibitor use, a meta-analysis of short-term clinical trials data suggested an increase in malignancy risk occurring within months of initiating therapy with monoclonal antibodies directed against TNF-α (infliximab and adalimumab).

Swefot Trial Suggests Adding TNF Inhibitor Better than Triple Therapy in RA Patients who do not Rapidly Respond to Methotrexate

August 26, 2009 By Arthritis Center

Initial combination therapy has been shown to be superior to step-up combination therapy in groups of RA patients; however, these findings are difficult to reconcile with the observation that many RA patients will have complete remission of disease on methotrexate alone. Practice patterns tend to emphasize initial treatment with methotrexate monotherapy, followed by the addition of other agents in combination for those with inadequate responses.

Effectiveness of Tai Chi for Musculoskeletal Pain Reviewed

June 4, 2009 By Jon Giles, MD

Tai Chi, a popular form of exercise involving stylized and controlled movements, has been advocated as a way to manage pain, maximize function, and improve quality of life for a variety of chronic musculoskeletal conditions, including osteoarthritis, rheumatoid arthritis, and fibromyalgia.  However, the evaluation of its efficacy in these conditions has been limited by the […]

Certolizumab Pegol Approved for the Treatment of Rheumatoid Arthritis

May 29, 2009 By Jon Giles, MD

The U.S. Food and Drug Administration has approved the use of certolizumab pegol (which will be marketed under the trade name Cimzia) for the treatment of moderate to severe rheumatoid arthritis (RA).  Certolizumab pegol is a novel TNF inhibitor comprised of an antigen-binding domain of a humanized TNF antibody coupled to polyethylene glycol (PEG) to […]

« Previous Page
Next Page »

Recent News

Exercise Tips for Arthritis Patients

Dr. Manno informs us on the background of the Johns Hopkins Rheumatology Exercise Center, as research was focused on muscle building

Risks and Benefits of Biologic Medications

Victoria Ruffing, RN, BC, Director of Patient Education at the Johns Hopkins Arthritis Center, shares the risks and benefits of biologic for

How to Manage Flares – Rheumatoid Arthritis

Through research, doctors have a clearer understanding of how flares can impact a patient on a personal and emotional level. Dr. Uzma Haque

Complementary & Alternative Medicines for Psoriatic Arthritis

There are many complementary & alternative medicines and practices that have been found to be beneficial in curbing arthritis pain,

I can’t be a runner because I have Rheumatoid Arthritis (RA), right?

Dr. Manno discusses running and Rheumatoid Arthritis. Is it an option for the RA patient?

News Categories

  • Ankylosing Spondylitis News
  • Fibromyalgia News
  • Gout News
  • Lupus News
  • Osteoarthritis News
  • Osteoporosis News
  • Psoriatic Arthritis News
  • Rheumatoid Arthritis News
U.S. News and World Report Rankings Badge

Connect With Us

  • Facebook
  • Twitter
  • YouTube
  • Johns Hopkins Rheumatology
  • Arthritis Center
  • Lupus Center
  • Lyme Disease Clinical Research Center
  • Myositis Center
  • Scleroderma Center
  • Sjogren’s Syndrome Center
  • Vasculitis Center

All information contained within the Johns Hopkins Arthritis Center website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.

Copyright Johns Hopkins Arthritis Center © 2019
Patient Privacy
Johns Hopkins Rheumatology